These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22614239)

  • 1. Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patients.
    Iwata A; Ikeda K; Hirose K; Takatori H; Takahashi K; Sanayama Y; Tanaka S; Suto A; Nakajima H
    Mod Rheumatol; 2013 Mar; 23(2):357-64. PubMed ID: 22614239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
    Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
    Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The impact of proton pump inhibitors on esophageal acid exposure in gastroesophageal reflux disease].
    Liang XY; Chen WN; Lan L; Wang Q; Lü YW; Lan Y
    Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):513-5. PubMed ID: 22943821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease.
    Sheikh I; Waghray A; Waghray N; Dong C; Wolfe MM
    Am J Gastroenterol; 2014 Jun; 109(6):789-94. PubMed ID: 24896751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
    Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
    Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
    van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
    Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
    Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A
    Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and symptom control in patients with GERD: US community-based survey.
    Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M
    Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors reduce the size and acidity of the acid pocket in the stomach.
    Rohof WO; Bennink RJ; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1101-1107.e1. PubMed ID: 24726906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms.
    Delshad SD; Almario CV; Chey WD; Spiegel BMR
    Gastroenterology; 2020 Apr; 158(5):1250-1261.e2. PubMed ID: 31866243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
    Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
    Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of proton pump inhibitors in patients with laryngopharyngeal reflux disease.
    Chiba T; Kudara N; Abiko Y; Endo M; Suzuki K; Sugai T; Ishijima K; Fukuda K; Yamazaki K; Sato H
    Hepatogastroenterology; 2011; 58(110-111):1580-2. PubMed ID: 21940324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
    Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.